<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01749046</url>
  </required_header>
  <id_info>
    <org_study_id>11-MPP02EPI</org_study_id>
    <secondary_id>11-МРР02ЕРI</secondary_id>
    <nct_id>NCT01749046</nct_id>
  </id_info>
  <brief_title>Remegal Fixed Dose as Adjunctive Therapy in Patients With Partial Seizures</brief_title>
  <official_title>Double-blind, Placebo-controlled Clinical Study to Evaluate the Efficacy, Safety and Tolerability of a Fixed Dose of Remegal as Adjunctive Therapy in Patients With Partial Seizures</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Valexfarm</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Valexfarm</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine weather Remegal in fixed dosage 1500 mg/daily is&#xD;
      effictive and safe in patients with epilepsy with partial seizures&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Phase III&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2012</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">October 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Seizure Frequency Reduction</measure>
    <time_frame>12 weeks</time_frame>
    <description>The assessment of efficacy will be based on the reduction of total partial seizure frequency reported in the patient's diary during the Treatment phase.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Seizure's-Free Days</measure>
    <time_frame>12 weeks</time_frame>
    <description>Number seizure's-free days during the Maintenance phase</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CGI</measure>
    <time_frame>12 weeks</time_frame>
    <description>Clinical Global Impression of change (CGI) at the end of Titration and Maintenance phases</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PGI</measure>
    <time_frame>12 weeks</time_frame>
    <description>Patients' Global Impression of change (PGI) at the end of the Titration and Maintenance phases</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>QOLIE</measure>
    <time_frame>14 weeks</time_frame>
    <description>Assessment of Quality of Life Instrument in Epilepsy (QOLIE) at the Baseline Visit and at the end of Maintenance Phase</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">224</enrollment>
  <condition>Epilepsy</condition>
  <condition>Simple Partial Seizures</condition>
  <condition>Complex Partial Seizures</condition>
  <condition>Partial Seizures With Secondary Generalization</condition>
  <arm_group>
    <arm_group_label>Remegal</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Remegal 1500 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Remegal</intervention_name>
    <description>Remegal 1500 mg for 12 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Remegal</arm_group_label>
    <other_name>Beprodon</other_name>
    <other_name>AED</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Man or woman, aged from 18 to 65&#xD;
&#xD;
          -  Diagnosis of epilepsy with simple and/or complex partial seizures both with or without&#xD;
             secondary generalization based on the ILAE classification&#xD;
&#xD;
          -  Results of at least one prior electroencephalogram (EEG) and magnetic resonance&#xD;
             imaging (MRI)/computerized tomography scan no more than 5 years should confirm the&#xD;
             diagnostic of partial seizures&#xD;
&#xD;
          -  If seizures are simple partial ones, only patients with motor signs must be enrolled&#xD;
&#xD;
          -  The onset date of partial seizures according to patient's report must be at least 2&#xD;
             years&#xD;
&#xD;
          -  The patient must report an average of at least 8 partial seizures per 56 days prior to&#xD;
             the baseline visit&#xD;
&#xD;
          -  The patient must not have seizure-free period longer than 21 days during the 8 weeks&#xD;
             prior to the baseline visit (i.e between V1 and V2)&#xD;
&#xD;
          -  Patients must have been treated with at least 2 different AEDs within the last 2 years&#xD;
             prior to the screening visit&#xD;
&#xD;
          -  The patient is capable and would like to respect all protocol requirements, include to&#xD;
             be available for the doctor's calls and doctor's appointments at any time, follow&#xD;
             through all protocol procedures&#xD;
&#xD;
          -  The patient agrees to self - report each seizure he has experienced between 2 visits,&#xD;
             accurately and thoroughly, in a diary he'll be provided with&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients suffering from non-epileptic seizures&#xD;
&#xD;
          -  Patients having seizures that can't be counted due to clustering.&#xD;
&#xD;
          -  History of primary generalized seizures&#xD;
&#xD;
          -  History of status epilepticus within 12 months prior to the screening visit&#xD;
&#xD;
          -  The patient has received not permitted concomitant medications&#xD;
&#xD;
          -  The patient has a progressive structural lesion in the CNS, or a progressive&#xD;
             encephalopathy&#xD;
&#xD;
          -  The patient is pregnant (or planning to become pregnant during the study) or is a&#xD;
             lactating woman&#xD;
&#xD;
          -  The patient has used Remegal previously or participated in a clinical study within 24&#xD;
             weeks prior to the screening visit&#xD;
&#xD;
          -  The patient has experienced of any somatic disorders or psychiatric diseases and&#xD;
             conditions which, in the opinion of the investigator, lead to health worsening or&#xD;
             influence on the patient ability to participate in the actual clinical study&#xD;
&#xD;
          -  Vulnerable patients and individuals of majority age who are subject to legal&#xD;
             protection or unable to express their consent&#xD;
&#xD;
          -  The patient has a history of chronic alcohol consumption or drug abuse within 2 years&#xD;
             prior to the screening visit&#xD;
&#xD;
          -  The patient has a known history of a severe anaphylactic reaction or severe changes in&#xD;
             blood tests&#xD;
&#xD;
          -  ALT, AST, alkaline phosphatise, total bilirubin or serum creatinine level ≥ 2 times&#xD;
             the upper limit of normal ranges&#xD;
&#xD;
          -  Clinically important abnormalities on physical examination, vital signs, ECG or&#xD;
             laboratory test results per-formed/obtained at the screening visit that may interfere&#xD;
             with patient's safety, compliance, or study evaluations, ac-cording to the&#xD;
             Investigator's opinion&#xD;
&#xD;
          -  The patient has a clinically significant disease, surgical condition or recent chronic&#xD;
             consumption of non-AED medications (within 4 weeks prior to the screening visit) that&#xD;
             might be reasonably expected to interfere with drug absorption, distribution,&#xD;
             metabolism, excretion&#xD;
&#xD;
          -  QTc interval on the ECG performed at the screening visit above 500 ms&#xD;
&#xD;
          -  Diseases or concomitant medications that may prolong QTc interval&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Sverdlovsk region neuropsychiatric clinic</name>
      <address>
        <city>Ekaterinburg</city>
        <zip>620036</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Region psychiatric clinic</name>
      <address>
        <city>Kemerovo</city>
        <zip>650036</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Moscow regional psychiatric hospital</name>
      <address>
        <city>Moscow</city>
        <zip>127083</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Medical University</name>
      <address>
        <city>Novosibirsk</city>
        <zip>630091</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State psychiatric hospital №6</name>
      <address>
        <city>Saint-Petersburg</city>
        <zip>193167</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Medical University</name>
      <address>
        <city>Samara</city>
        <zip>443099</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Republican psychiatric dispensary</name>
      <address>
        <city>Saransk</city>
        <zip>430030</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Medical Academy</name>
      <address>
        <city>Smolensk</city>
        <zip>214019</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical unit of disel equipment</name>
      <address>
        <city>Yaroslavl</city>
        <zip>150007</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <study_first_submitted>December 11, 2012</study_first_submitted>
  <study_first_submitted_qc>December 11, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 13, 2012</study_first_posted>
  <last_update_submitted>May 10, 2017</last_update_submitted>
  <last_update_submitted_qc>May 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Epileptic seizures, Partial seizures</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Seizures</mesh_term>
    <mesh_term>Epilepsies, Partial</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

